Effect of budesonide oral suspension on dysphagia and esophageal inflammation in eosinophilic esophagitis: a systematic review and meta-analysis

1

Eosinophilic esophagitis (EoE) is characterized by eosinophilic inflammation and symptoms like dysphagia and food impaction.
2

Budesonide oral suspension (BOS) is a topical corticosteroid designed to enhance mucosal contact and reduce inflammation in EoE.
3

The systematic review included four randomized controlled trials with a total of 523 patients comparing BOS to placebo.
4

BOS significantly improved histologic outcomes, endoscopic severity, and patient-reported symptom severity compared to placebo.
5

Treatment-emergent adverse events were similar between BOS and placebo groups, with serious adverse events being rare.

Frontiers In Immunology

by Darío S. López Delgado, Carlos A. Narváez, Gloria L. Chapues-Andrade, María A. Matus-Hernández, Veraliz González-Hidalgo, Gerson Diaz-Gonzales, Oriana Rivera-Lozada, Joshuan J. Barboza
July 8, 2026

1